|
Synonyms: 7E3 antibody | antiGPIIBIIIa | C7E3 | ReoPro®
abciximab is an approved drug (FDA (1994))
Compound class:
Antibody
Comment: Abciximab is a chimeric human-murine monoclonal antibody Fab (fragment antigen binding) fragment designed to target glycoprotein IIb/IIIa receptor, a key mediator of platelet aggregation and clot formation [2]. The invention of abciximab is covered by patent US5976532 [1], where its originating antibody is coded c7E3.
View more information in the IUPHAR Pharmacology Education Project: abciximab |
| Bioactivity Comments |
| Detailed information contained in the covering patent [1] describes in vitro and in vivo activity of abciximab, which supports its action as an anti-thrombotic agent. However, no affinity data is provided for the interaction between abciximab and its molecular target. |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Ligand mentioned in the following text fields |
| Integrins overview |
